NCT05365425View on ClinicalTrials.gov

Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

PHASE4RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
DyslipidemiaAtherosclerosisDiabetes Mellitus, Type 2
Interventions
DRUG

Choline fenofibrate

choline fenofibrate 178.8mg (135mg as fenofibric acid)

DRUG

Policosanol

policosanol 10mg

Trial Locations (1)

13620

RECRUITING

SNUBH, Seongnam-si

Sponsors
All Listed Sponsors
collaborator

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

lead

Seoul National University Bundang Hospital

OTHER